Crystal Structure
Crystallisation Method: EM
Corresponding Chain: A/B/C/D
Sequence Length: 66-1179
Detail: Struture Info
General Information of DT | |||||
---|---|---|---|---|---|
DT ID | DTD0512 | ||||
Gene Name | KCNMA1 | ||||
Protein Name | Calcium-activated potassium channel subunit alpha-1 | ||||
Gene ID | |||||
UniProt ID | |||||
TCDB ID | |||||
3D Structure |
Crystal Structure Crystallisation Method: EM Corresponding Chain: A/B/C/D Sequence Length: 66-1179 Detail: Struture Info |
||||
Synonyms | BK channel; BKCA alpha; BKTM; CADEDS; Calcium-activated potassium channel, subfamily M subunit alpha-1; K(VCA)alpha; KCNMA; KCNMA1; KCa1.1; Maxi K channel; MaxiK; PNKD3; SAKCA; SLO; Slo homolog; Slo-alpha; Slo1; Slowpoke homolog; bA205K10.1; hSlo; mSLO1 | ||||
DT Family | Voltage-Gated Ion Channel (VIC) Superfamily ; | ||||
Tissue Specificity | Widely expressed. Except in myocytes, it isalmost ubiquitously expressed. | ||||
Function | This transporter contributes to repolarization of the membrane potential and controls excitability in a number of systems, such as regulation of the contraction of smooth muscle, the tuning of hair cells in the cochlea, regulation of transmitter release, and innate immunity. Potassium channel activated by both membrane depolarization or increase in cytosolic Ca(2+) that mediates export of K(+). It is also activated by the concentration of cytosolic Mg(2+). Its activation dampens the excitatory events that elevate the cytosolic Ca(2+) concentration and/or depolarize the cell membrane. In smooth muscles, its activation by high level of Ca(2+), caused by ryanodine receptors in the sarcoplasmic reticulum, regulates the membrane potential. In cochlea cells, its number and kinetic properties partly determine the characteristic frequency of each hair cell and thereby helps to establish a tonotopic map. Kinetics of KCNMA1 channels are determined by alternative splicing, phosphorylation status and its combination with modulating beta subunits. Highly sensitive to both iberiotoxin (IbTx) and charybdotoxin (CTX). | ||||
Endogenous Substrate(s) | Potassium ions | ||||
Variability Data of This Drug Transporter (DT) | |||||
Regulatory Variability Data of This DT (VARIDT 3.0) |
|||||
(β) Post-translational Modification of This DT |
|||||
(γ) Transcriptional Regulation of This DT |
|||||
(δ) Epigenetic Regulation of This DT |
|||||
(ε) Exogenous Modulation of This DT |
|||||
Structural Variability Data of This DT (VARIDT 2.0) |
|||||
(α) Mutation-induced Structural Variation |
|||||
(β) Inter-species Structural Differences |
|||||
General Variability Data of This DT (VARIDT 1.0) |
|||||
(α) Genetic Polymorphisms of This DT |
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.